Literature DB >> 25356184

Successful use of bevacizumb and paclitaxel in a male breast cancer with liver metastases.

Du-Ping Huang1, Xiao-He Ye2, Chun Jin1.   

Abstract

Breast cancer in men is a rare cancer manifestation. In this article we report a case of male breast cancer with liver metastases, which showed a good response to a combined treatment of bevacizumb and paclitaxel, suggesting a useful option for the first-line treatment of patients with recurrent HER2-negative male breast cancer. And further assessment in a randomized clinical trial is needed.

Entities:  

Keywords:  Male breast cancer; bevacizumb; liver metastases

Year:  2014        PMID： 25356184      PMCID： PMC4211834     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN： 1940-5901


  21 in total

Review 1.  Bevacizumab in the treatment of metastatic breast cancer: friend or foe?

Authors:  Alberto J Montero; Mauricio Escobar; Gilberto Lopes; Stefan Glück; Charles Vogel
Journal:  Curr Oncol Rep       Date:  2012-02       Impact factor: 5.075

2.  Poorer survival outcomes for male breast cancer compared with female breast cancer may be attributable to in-stage migration.

Authors:  Jennifer L Gnerlich; Anjali D Deshpande; Donna B Jeffe; Susmitha Seelam; Eric Kimbuende; Julie A Margenthaler
Journal:  Ann Surg Oncol       Date:  2010-12-14       Impact factor: 5.344

3.  Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.

Authors:  L G Presta; H Chen; S J O'Connor; V Chisholm; Y G Meng; L Krummen; M Winkler; N Ferrara
Journal:  Cancer Res       Date:  1997-10-15       Impact factor: 12.701

4.  Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro.

Authors:  Yaning Wang; David Fei; Martin Vanderlaan; An Song
Journal:  Angiogenesis       Date:  2005-05-09       Impact factor: 9.596

5.  Bevacizumab improves the delivery and efficacy of paclitaxel.

Authors:  Mieko Yanagisawa; Keigo Yorozu; Mitsue Kurasawa; Kohnosuke Nakano; Koh Furugaki; Yoriko Yamashita; Kazushige Mori; Kaori Fujimoto-Ouchi
Journal:  Anticancer Drugs       Date:  2010-08       Impact factor: 2.248

6.  Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

Authors:  David W Miles; Arlene Chan; Luc Y Dirix; Javier Cortés; Xavier Pivot; Piotr Tomczak; Thierry Delozier; Joo Hyuk Sohn; Louise Provencher; Fabio Puglisi; Nadia Harbeck; Guenther G Steger; Andreas Schneeweiss; Andrew M Wardley; Andreas Chlistalla; Gilles Romieu
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544

Review 7.  Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship.

Authors:  K J Ruddy; E P Winer
Journal:  Ann Oncol       Date:  2013-02-20       Impact factor: 32.976

8.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

Review 9.  Male breast carcinoma: increased awareness needed.

Authors:  Jonathan White; Olive Kearins; David Dodwell; Kieran Horgan; Andrew M Hanby; Valerie Speirs
Journal:  Breast Cancer Res       Date:  2011-09-29       Impact factor: 6.466

Review 10.  Male breast cancer: is the scenario changing.

Authors:  Kaiyumars B Contractor; Kanchan Kaur; Gabriel S Rodrigues; Dhananjay M Kulkarni; Hemant Singhal
Journal:  World J Surg Oncol       Date:  2008-06-16       Impact factor: 2.754
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.